and differ by only a few amino acid substitutions, including serine at position 203, which plays a key role in the GPI anchorage of F~yR111B.l~ FcyRIIIB bind complexed human IgG 1, IgG3, but not IgG2 and IgG4.I6x2O Two FcyRIIIB alleles exist, NAl and NA2, the NA2 form having two additional glycosylation sites at position 65.5,'9,2L Neutrophils, which express FcyRII and FC~RIIIB,~~'' represent the most abundant cell type of the immune system. These cells are involved in primary immune defenses against bacterial infections and in the uptake of immune complexes. Binding of IgG-opsonized particles via neutrophil Fcy RII activates respiratory burst, release of granule proteins and IgG-dependent phagocyt~sis.'~ FcyRIIIB ulated by pokeweed mitogen (PWM) in vitro. FACS analysis showed that biotinylated sCDl6 bound specifically to a fraction (35%) of PBMC, which corresponds to monocytes and to subsets of B and T lymphocytes. Moreover, sCDl6 did not modify the staining of PBMC by FITC-coupled PWM. Thus, the biologic function(s) of sCDl6 on PWM-induced responses are exerted through direct and specific interaction(s) with mononuclear blood cells and not with PWM. In conclusion, neutrophils may play a regulatory role on immune responses via the production of soluble forms of CDI 6 with cell-binding and antiproliferative capacities.
Human neutrophils express two types of low affinity receptors for IgG, FcyRll or CD32 and FcyRIIIB or CD16. Human serum contains soluble C D I 6 (sCD16), which is produced by proteolysis of neutrophil FcyRIIIB, the cleavage site being located close to the cell surface. In order to assess the functional roles of sCDl6, we have produced, in eukaryotic cells, a recombinant sCDl6 containing the extracellular region of FcyRIIIB. Purified sCDl6, of molecular mass of 48 kD, bound human lgGl and lgG3 but not 1962, lgG4, or F(ab),. It inhibited, in a time and dose-dependent fashion, proliferation and IgM and IgG production of human peripheral blood mononuclear cells (PBMC) stim-ECEPTORS FOR THE Fc portion of IgG (FcyR) are a R heterogeneous group of membrane glycoproteins that mediate important effector and regulatory functions within the immune system.' Three distinct, but closely related, classes of FcyR, all belonging to the Ig supergene family, have been described.' They differ in ligand affinity, cellular distribution, and function.2 Whereas FcyRI are high affinity receptors for monomeric IgG, FcyRII and 111 are low affinity receptors bidding complexed IgG. 3 In humans, several monomeric FcyRII isoforms (CD32) are encoded by three genes and expressed by neutrophils, monocytes, and platelek2 The two types of FcyRIII (CD16), FcyRIIIA and Fcy RIIIB, have distinct structure and cellular expression."6 FcyRIIIA is a transmembrane multimeric receptor composed of a ligand-binding chain noncovalently associated with homo or hetero dimers of y chains and/or { chains. The y and the { chains are also present in the high affinity receptor for the Fc portion of IgE (FctRI) and in the TcR/ CD3 complex, re~pectively.'~~ FcyRIIIA is expressed by natural killer (NK) cells, macrophages, and cultured monoc y t e~.~,~ Ligand-induced cross-linking of Fcy RIIIA elicits cell activation'@'' and triggers antibody-dependent cell-mediated cytotoxicity (ADCC) in NK cells and monocytes, and phagocytosis in macrophage^.'^,'^ FcyRIIIB is a single chain receptor expressed exclusively by neutrophils and anchored to the plasma membrane by a glycosyl-phosphatidyl-inositol (GPI)
FcyRIIIB and the ligandbinding a chain of FcyRIIIA are encoded by two nearly identical, linked genes:5 and differ by only a few amino acid substitutions, including serine at position 203, which plays a key role in the GPI anchorage of F~yR111B.l~ FcyRIIIB bind complexed human IgG 1, IgG3, but not IgG2 and IgG4.I6x2O Two FcyRIIIB alleles exist, NAl and NA2, the NA2 form having two additional glycosylation sites at position 65.5, '9,2L Neutrophils, which express FcyRII and FC~RIIIB,~~'' represent the most abundant cell type of the immune system. These cells are involved in primary immune defenses against bacterial infections and in the uptake of immune complexes. Binding of IgG-opsonized particles via neutrophil Fcy RII activates respiratory burst, release of granule proteins and IgG-dependent phagocyt~sis.'~ FcyRIIIB binds IgG-immune complexes and participate in their uptake.24 Binding of monoclonal antibodies (MoAbs) or complexed IgG to Fcy RIIIB induces increase in intracellular calciumz5 and the release of lysosomal enzymes.26 How the GPI-linked FcyRIIIB receptor transduces these signals across the lipid bilayer is still unclear. It is quite possible that FcrRII participate in these processes."
One of the remarkable properties of FcyR is the existence of soluble forms that bind complexed IgG. In humans and in mice, soluble forms of low affinity FcyR (sFcyR) have been described in culture supernatants of blood cells2' as well as in biologic fluids such as serum and s a l i~a . '~,~~,~~ In humans, the majority of serum sFcyRIII (sCD16) is produced by neutrophils, because patients in whom the expression of membrane CD16 is low because of a defect in PIlinkage of cell surface protein^,'^,^' or patients deficient in the FcyRIIIB gene,32 have low or undetectable levels of sCD16, respectively. A decrease of sCD16 has been observed in the sera of patients with bone marrow diseases such as multiple myeloma33 and paroxysmal nocturnal hemoglobinuria (PHN).31 Activated neutrophils release sCDl6 by proteolysis of the GPI-linked receptor, the cleavage site being located close to the cell ~u r f a c e . ' In view of these findings and to further define the role of FcyRIIIB on neutrophils, it would be useful to determine the functional roles of sCD16. In the present study, we have produced a recombinant sCD 16 by transfection of eukaryotic cells with an FcyRIIIB cDNA (NA2 allele) mutated by insertion of a stop linker. Recombinant sCD16 containing theextracellular region ofFcyRIIIB was purified to homogeneity and its IgG-binding capacities as well as its biologic activities on PWM-stimulated responses were investigated. We show that recombinant sCD16 inhibits PWM-stimulated antibody production by human peripheral blood mononuclear cells (PBMC). By using biotinylated sCD16, a specific binding of sCD 16 to a fraction of PBMC could also be demonstrated indicating that sCD I6 exerts its inhibitory activities on PWM-induced responses through direct interaction with mononuclear blood cells and not with PWM. TAG) at position 652 (Kpnl site) of cDNA encoding the membrane form of FcyRIIIB, NA2 form. 16 This results in the addition of six accessory amino acid residues, ADPRLV, before reaching the termination codon. The cDNA insert is predicted to encode a protein with 194 amino acid residues that contains the two extracellular Ig-like domains. The Xba-Xba mutant cDNA was introduced into the polylinker site of pKC3, a vector derived from pKO ne^.^' Mouse L cells were transfected with IO jtg ofpKC3 cDNA and with 100 ng of pSV2 neo as selection vector, using the calcium-phosphate coprecipitation method as previously described."
MATERIALS AND METHODS

Preparation
Total RNA from G-4 I8 ( 1 mg/mL; GIBCO, Paisley, UK) resistant clones was tested for the presence of RNA encoding sCD16 by a dot-blot assay using a specific probe (Xba-Xba fragment ofpKC3 cDNA) labeled with [a-"P] dCTP (370 mBq/mL; Amersham, UK) by the random primer method.40 Several positive clones were obtained. One ofthem, IIIC8, containing the highest amount of RNA encoding sCD16, was used for further studies. IIIC8 cells were maintained at 37°C in a humidified atmosphere containing 5%
Cot, in Dulbecco's modified Eagle's medium (DMEM; GIBCO) supplemented with 100 U/mL penicillin (P) and 100 jtglmL strep tomycin (S), 2 mmol/L L-glutamine (L-GIu),' and 10% fetal calf serum (FCS Flow Laboratories, Asnikres, France) and containing the antibiotic (3-418 at 500 jtg/mL. Prodticlion and pzrri/ication of sCDI6. To produce large amounts of sCD16, IIIC8 cells were grown in a perfusion cell culture system (Acusyst Jr, Endotronics Inc, Minneapolis, MN), which allows the permanent control ofpH. dissolved oxygen, and residual glucose during culture. The I. (BSA)-sepharose 4B column (Pharmacia, Uppsala, Sweden), and applied at I5 to 20 mL/h, at 4"C, on a column containing0.5 mL of Sepharose 4B coupled with the MoAb 3G8 (a mouse IgG1, k directed against CD16)'* equilibrated in the same buffer. After three passages, the effluent was collected and the column washed with 80-fold volume 20 mmol/L tris-base-buffer pH 7.6. Elution was performed at 3 mL/h using 0.2 mol/L glycine-HC1-buffer, pH 2.8. The eluates were neutralized with 2 mol/L tris-base-buffer, pH 9. Serial dilutions of the starting material, effluents, and acid eluates were tested for protein concentration by a mini Bradford microassay (Bio-Rad Protein Assay, Munchen, Germany) and for the presence of sCD16 by immunodot assay on nitrocellulose using '*%la-beled CD16 MoAb-BW209/2 (a mouse IgG2a directed against CD16). A mean of 120 k 76 pg of protein was obtained from 100 mL of harvested culture medium. Results ofthe immunodot assays showed that the recoveries of the affinity chromatography purification step were between 16% and 30%, depending on the preparation (data not shown), and that this step led to a 200-fold enrichment in sCD 16. Eluates were dialyzed against phosphate-buffered saline (PBS) and frozen in aliquots at -20°C. Purity of sCD16 was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) followed by Coomassie Blue or Silver staining of the polyacrylamide gels. In some experiments control eluates prepared by passing culture medium of nontransfected L cells on insolubilized 3G8 were prepared. For immunofluorescence studies, 500 pg sCD16 was coupled to biotin (IBF Biotechnics, VilleneuveLa-Garenne, France) according to the manufacturer instructions. Deglycosylation ofsCDI6. Ten micrograms of sCD16 was incubated for 18 hours at 37°C with I U of PNGase F (N-Glycosidase, Biolabs, Beverly, MA) in manufacturer's conditions or with one unit of N-glycanase (Genzyme, Cambridge, MA) after addition of SDS (0.1% final concentration) and boiling for 5 minutes. After boiling in 80 mmol/L tris-HCl-buffer, pH 6.8, containing 100 mmol/L DTT, 2% SDS, 10% glycerol, and 0.01% Bromophenol Blue (SDS sample buffer), the samples were subjected to SDS-PAGE followed by coomassie blue staining.
One-dimensional SDS-PAGE and Western blotting analysis. One dimensional SDS-PAGE was performed on 10% polyacrylamide gels according to Laemmli4' and using a minilab gel system (Mini-Protean I1 Electrophoresis cell; Bio-Rad, Richmond, VA). For Western blotting analysis, 30 pL of unlabeled purified sCD16 or control eluates (0.1 mL) was boiled for 3 minutes in SDS sample buffer and applied on 10% polyacrylamide gels and SDS-PAGE was performed at room temperature for 45 minutes at 200 V. Gels were washed in 25 mmol/L tris-base-buffer, pH 8.3, containing 192 mmol/L glycine, 2% methanol, and transferred onto X-OMAT S film (Eastman Kodak, Rochester, NY) for autoradiogBindingspecifciryofsCD16. In some experiments monoclonal IgG coupled to Sepharose 4B were used for binding studies. After dialysis against 20 mmol/L tris-base-buffer, pH 7.6, the culture medium was precleared by passage on a 0.5 mL BSA-sepharose column and applied on 0.5 mL of sepharose coupled with the following human IgG myeloma (6 mglmL sepharose):IgGI-kappa (Leu, kindly provided by Dr C. Mathiot, lnstitut Curie, Paris, France), IgG2-kappa, IgG3-kappa, IgG4-kappa (The Binding site, Immunotech, Marseilles, France) or with F(ab')2 fragments of human polyclonal IgG, prepared by pepsin digestion ofhuman IgG andchromatography on protein A-sepharose CL-4B (Pharmacia, Sweden). F(ab'), fragments were pure as judged by Coomassie Blue staining after SDS-PAGE. Immunoadsorbents were washed with 20 mmol/ L tris-base-buffer pH 7.6. sCD16 was eluted in 0.2 mol/L glycine-HCI-buffer, pH 2.8, and neutralized with 2 mol/L tris-base-buffer pH 9. Fifty microliters of the starting material, effluents, and the acid eluates was then tested by immunodot assay using '2SI-labeled CD16 MoAbBW209/2.
PBMC preparation and P WM-induced responses. PBMC were obtained by Ficoll-Isopaque density gradient separation of mononuclear cell enriched fraction (HBtel Dieu, Blood Bank, Paris, France) from healthy adult defibrinated peripheral blood. Cultures were performed from thawed PBMC (usually containing >90% of viable cells as tested by trypan blue exclusion) at 37OC in a humidified atmosphere of 7% C02, in 96-well microtiter plates (FALCON 3072; Becton Dickinson, Mountain View, CA). PBMC were resuspended (2 X IO6 cells/mL) in RPMI-1640 (GIBCO) supplemented with 10% FCS (Flow Laboratories, Asni&res, France), 100 U/mL (P), 100 pglmL (S), 2 mmol/L L-Glu, 50 mmol/L 8-2 mercaptoethanol (GIBCO) and 1% of nonessential amino acids (MEM; GIBCO). Each culture was performed in triplicate by incubating 2 X IO5 cells in the presence of PWM (0.1 pglmL; IBF, Villeneuve-la Garenne, France), in 200 pL (final volume) of medium for 6 days with different amounts of sCD16 or with control PBS. In some experiments, monoclonal CD16 antibody (3G8) or irrelevant murine monoclonal lgGl (7.6) was added to the cultures. At day 6, raphy.
For 
RESULTS
Biochemical characteristics of sCD16 secreted by IIIC8 cells. A clone, named IIIC8 and containing a large amount of mRNA encoding sCDl6 was selected and grown in a perfusion cell culture system. Recombinant sCD16 was purified by affinity chromatography of harvested culture medium on insolubilized CD16 MoAb-3G8 and analyzed by SDS-PAGE under reducing conditions. As shown in Fig  1 A, sCD 16 migrated as a broad band corresponding to 44 to 54 kD with a maximum at 48 kD. The same results were obtained under nonreducing conditions (data not shown). Deglycosylation of this material with PNGase or N-glycanase led to the appearance of two bands corresponding to 26-and 30-kD polypeptides, respectively (Fig 1A) . sCD16 and control eluate were also analyzed by Western blotting using 1251-labeled CD16 MoAb-BW20912. As shown in Fig IB, sCD16 migrated as a glycoprotein with a maximum corresponding to 48 kD, whereas no material was detectable in the lane with control eluate.
Isotypic specijicity of sCDI6. To assess the isotypic specificity of sCD16, culture medium harvested from the bioreactor was applied on sepharose beads coupled to human IgG isotypes or to F(ab), fragments of human IgG. Starting material, effluents, as well as acid eluates were tested for the presence of sCD I6 by immunodot assay using 1251-labeled CD16 MoAb-BW20912. As shown in Fig 2, intense spots were detected in the acid eluates from insolubilized IgGl and IgG3 immunoadsorbents, whereas those from insolubilized IgG2, IgG4, and F(ab'), were negative. Compared with the starting material, the effluents of IgG2, IgG3, IgG4, and F(ab'), immunoadsorbents gave spots of similar intensity, while that of IgG 1 immunoadsorbent gave a spot of lesser intensity. These data indicate that sCD 16 binds to insolubilized human IgGl and IgG3 but not significantly to insolubilized IgG2, IgG4, and F(ab),.
Inhibition of Ig production and cell prolifeation by PWM-stimulated PBMC. Various doses of five distinct preparations of affinity-purified sCD 16 (98% pure) were added at day 0 to cultures of PBMC stimulated by PWM. At day 6, IgM and IgG were measured in cell supernatants by isotype specific ELISA. As shown in Table I , addition of doses of sCD16 at 1.5 pg/mL and 6.2 pg/mL led to almost complete inhibition (from 89% to 100%) of IgM and IgG secretion. The presence of a smaller dose (12 ng/mL) of recombinant product in cell cultures led, with two preparations (experiments I and 5), to partial inhibition of IgM (1 8% and 69%) and IgG (59% and 69%) secretion but had no significant effect with the other three preparations (experiments 2 through 4). In triplicate cell cultures, proliferation was measured on the same day by 13H] thymidine incorporation. As shown in Table 1 , with the five preparations, a high dose of sCD16 (6.2 pg/mL) was required to inhibit cell proliferation (from 89% to loo%, depending on the preparation). With some other preparations, although Ig production was reproducibly inhibited, inhibition of proliferation was less consistently found (data not shown). To investigate the specificity of the inhibition of cell proliferation exerted by sCD16, anti-CD16 MoAb 3G8 (75 pg/mL) was added at day 0 to cell cultures performed in the presence of 3.1 pg/ mL sCDl6. The addition of the anti-CD 16 MoAb 3G8 almost totally reversed (74%) the inhibition exerted by a high dose of sCD16, while an irrelevant isotype-matched IgG had no effect (Fig 3) . The effects of sCD16 on PWM-induced responses were compared more precisely by adding, at day 0, serial ' / z dilutions of the recombinant product on PWM-induced responses. As shown in one representative experiment illustrated in Fig 4, concentrations of sCD16 required for inhibition of [3H] thymidine incorporation, IgM and IgG secretion were clearly different. Whereas a dose of 6 ng/mL of sCD16 was sufficient to inhibit IgG production by 50%, 50% inhibition of IgM secretion required 83-fold more product (500 ng/mL), and 50% inhibition of [3H] thymidine incorporation 750-fold more product (4.5 pg/mL).
Kinetics of the suppressive efect of sCD16 on PWM-induced responses. Recombinant sCD 16 was added several days after initiation of PWM-stimulated cell cultures. Cell proliferation and Ig secretion were measured at day 6 as described above. Addition of sCD16 at 6.2 pg/mL from day 2 to day 5 led to a progressively decreasing inhibitory effect on cell proliferation (Fig 5) . Indeed, no significant modification of [3H] thymidine incorporation was observed when sCD16 was added at day 6 (1 1% of inhibition). A similar phenomenon was observed on Ig secretion. Addition of 6.2 pg/mL of sCD 16 at day 3 always had an inhibitory effect on IgM (mean f SD: 87% f 11%) and IgG (mean ? SD: 90% ? 17%) secretion but no inhibition was observed with sCD I6 at 12 ng/mL ( Table 2) . When added at day 4, sCD 16 at 6.2 Fg/mL had a smaller or no inhibitory effect on IgM and IgG production (52% and 0%, respectively) (data not shown).
The binding of sCD16 to unstimulated PBMC was investigated by indirect immunofluorescence using sCD 16 coupled to biotin and streptaviBinding of sCDl6 to PBMC. For din-phycoerythrin conjugate as second step reagent. Analysis by FACS showed that a subpopulation ofPBMC-35%-bound sCD16 (Fig 6A) . In addition to the peak corresponding to background fluorescence (sCD 16 negative) (mean fluorescence index [MFI] = 36), two peaks were obtained: a minor one of intermediate fluorescence intensity (sCD16 int) (MFI = 1 IO), and a major one of bright intensity (sCD16 hi) (MFI = 156). The specificity of the binding of biotinylated sCD I6 to PBMC was analyzed next by adding increasing doses of unlabeled sCD 16 to the incubation mixture. As shown in Fig 6B (a through f) , fluorescence intensity decreased progressively in the presence of increasing doses of unlabeled molecule, and reached negative control values for 150-fold molar excess of competitor. Preincubation with the same dose of ovalbumin as control protein had no significant effect on the binding of biotynilated sCD16 (data not shown). As shown in Fig 6C, analysis by two-dimensional scatter (size and granulosity) showed that the sCD16-positive cells contained two populations: a minor one (23% of positive cells) of small size and granulosity, and a major one (77% of positive cells) of large size and high side scatter values. The cells that did not bind sCD16 were of small and intermediate size and of small granulosity (Fig 6C) . Thus, these experiments showed that sCD 16 binds to large and granular mononuclear cells and, to a minor extent, to cells of small size and granulosity.
To investigate whether sCD16 interfere with the interaction between PWM and PBMC, the effect of sCD16 on the binding ofFITC-coupled PWM to PBMC was measured. As shown in Fig 7, preincubation with 40 pg/mL sCD 16 did not modify significantly fluorescence intensity profiles obtained with FITC-PWM.
Double labeling experiments were then performed by using antibodies against monocytes (CD14), T and NK cells (CD7) and B cells (CD19). As shown in Fig 8A, most of the sCD 16 int were CD 14 positive and the sCD I6 hi were CD 14 negative. A subset of the sCD16 hi expressed CD7 marker and most of the sCD16 int were CD7 positive (Fig 8B) . (Fig 8C) . Altogether, these data showed that sCD 16 binds to monocytes, a subset of T cells and a subset of B cells. For personal use only. on October 30, 2017. by guest www.bloodjournal.org From FcyRIIIB inhibits Ig secretion and cell proliferation of PWM-stimulated PBMC. The recombinant molecule was isolated by affinity chromatography, on insolubilized 3G8 MoAb, using culture medium from the IIIC8 clone grown in a perfusion cell culture system. Depending on the preparation, total amounts of 120 k 76 pg sCD16 were obtained from 100 mL harvests. Because recovery of the purification step was approximately 25%, the bioreactor should produce 4.8 mg/L of sCD16. Similar levels were obtained previously in the same production system with CulB3, a clone of L cells secreting recombinant murine s F c~R I I .~' ,~~ When analyzed by SDS-PAGE, sCD16 was 95% to 98% pure and its apparent M, was between 44,000 and 54,000. Similar results were observed when preparations of sCD 16 were analyzed by Coomassie blue and by silver staining of polyacrylamide gels, or when L251-labeled sCD 16 was used (data not shown).
Western blotting analysis showed that the purified material reacted with the CD 16 MoAb, BW209/2. After deglycosylation by N-glycosidases, sCD 16 glycoproteins resolved into two polypeptides with M, of 26,000 and 30,000, respectively. These two polypeptides were present even at higher doses of glycosidases or after longer incubation times (data not shown). Because the sequence of the cDNA encoding sCD16 was the one expected (data not shown), the smallest polypeptide may correspond to a degradation product or the other one to an incompletely deglycosylated one. Similar results have been obtained by other investigators.' The present data are compatible with the predicted structure ofa soluble form ofCD16 with six putative N-glycosylation sites on a 194 amino acid polypeptide chain (theoretical size 25.3 kD). The analysis of the binding specificity of sCD16 toward human IgG subclasses in insolubilized form indicated that it binds to IgGl and IgG3 but not significantly to IgG2 and IgG4 and F(ab),. The fact that sCD16 has the same isotypic specificity towards human IgG subclasses as membrane CDl 620 and that it reacts both with the CDI 6 MoAb, BW209/2 and with 3G8, an MoAb that recognizes a conformational epitope on CD16 (data not shown), suggests that the recombinant soluble FcyR has retained the overall structure of the extracellular portion of the entire receptor. Similarly, and in agreement with previous observations concerning the membrane CD 1 6,43 sCD 16 bound 12'I-labeled Con A and this binding was specifically inhibited in the presence of aD-Mannose, as shown by Western blot (data not shown).
sCD16 exerted a significant inhibition of IgG and IgM production in PWM-stimulated PBMC cultures. The effects were dose dependent and observed with five distinct preparations of sCD16, and on two different PBMC donors. The addition of sCD16 in the ELISA plates together with the culture control supernatants did not interfere with the quantification of Ig (data not shown). Cell proliferation was significantly inhibited by the various preparations of sCDl6. No modification of ['HI thymidine incorporation was observed after addition of the product on the last day of cell cultures suggesting that these inhibitory effects on cell proliferation and Ig secretion are not due to direct cellular toxicity exerted by sCD16. Analysis of cell viability at day 6 of PWM-stimulated cultures by a trypan blue exclusion assay confirmed this explanation. First, when sCD16 was added at day 0 at a concentration of 12 ng/mL, no detectable inhibition of cell viability was observed (50% of cell viability as compared with 55% for positive control), although total inhibition of IgG secretion was obtained. Second, in cultures that carried out the presence of sCD16 at 6.2 pg/mL, a dose that led to a significant inhibition of cell proliferation and Ig secretion, cell viability was not significantly affected as compared with the control cultures (55% of cell viability), when the product was added at day 3 or 4, and only partially (25% of cell viability) when sCD16 was added at day 0 or 2. Thus, even at this concentration, inhibition of Ig secretion and cell proliferation was not due to direct toxic effects of sCDl6. Ifthis were the case, cell viability would be affected regardless of the day on which the product was added. Thus, it seems that the 40% inhibition of cell viability observed after addition of the product at day 0 is a consequence, rather than a cause, of the inhibition of cell proliferation. It is also possible that the suppressive effect of the recombinant product is due to the presence of biologically active contaminants, such as TGFp,44 which may copurify with sCD16. However, the fact that addition of the CD16 MoAb, 3G8, reverted the inhibition of cell proliferation by sCD 16 rules out this possibility. It is noteworthy that, at a low dose, sCD16 only inhibited IgG responses and may therefore constitute an "isotype specific" suppressive factor.'228 This observation is reminiscent ofprevious studies showing that sFcyR produced by human lymphocytes and neutrophils suppresses IgG secretion but not IgM secretion or cell proliferation in PWM-and Nocardia opaca-induced response^.^^-^'
The present study demonstrates for the first time that pure recombinant sCD 16 downregulates PWM-induced responses. Murine sFcyRII was previously shown to inhibit antibody production in secondary anti-SRBC responses in vitro34 as well as polyclonal Ig production by pure B cells stimulated by anti-IgM plus IL2, IL4 and IL5.I The mechanisms by which sCD16 suppresses the PWM-induced responses are still unclear. However, FACS analysis using biotinylated sCD16 showed that the recombinant product bound specifically to approximately one third of PBMC without interfering with the binding of PWM, demonstrating that it does not exert its antiproliferative effect by inhibiting the interaction of PWM with PBMC. sCD16 bound to most, if not all, large and granular mononuclear cells. These cells most probably contain LGL, activated lymphocytes, and monocytes. sCD 16 bound also to a fraction (1 3%) of mononuclear cells of small size and granulosity, which most likely correspond to resting lymphocytes. Double labeling experiments showed that monocytes, and a fraction of T and B cells, bound sCD16. Thus, sCD16 is capable of interacting with several cell populations within PBMC.
It has been shown that the cross-linking of surface Ig with FcyRII is a negative signal for B cells.45 It is thus conceivable that, at low doses of sCD16, the binding to B lymphocytes occurs via membrane IgG. Alone, or complexed with secreted IgG, it may favor the cross-linking of membrane IgG and FcyRII and thus deliver a negative signal for B
cells. Because the proportion of dividing IgG-positive cells is
For personal use only. on October 30, 2017. by guest www.bloodjournal.org From low, no effect is seen on cell proliferation. At higher doses, sCD 16 may also bind cells with no cell surface IgG via other glycosylated cell surface molecules, since it binds to lectins such as Con A, or via hydrophobic interactions. IgG-negative B cells could then bind immune complexes, which then inhibit cell proliferation and, as a consequence, IgM secretion. On the other cell types that bind sCD 16 (T cells and/or monocytes), sCDl6 may act indirectly via the induction of antiproliferative factors, such as TGFp" or Noteworthy, sCD 16 at doses up to 10 pg/mL did not exert any significant effect on the proliferative responses induced by PHA (data not shown).
In mice and in humans, soluble FcyR have been detected in biologic fluids. In human serum, sCD16 is derived from activated neutrophil^.'^,^^ It is produced by proteolysis of 
